Nov. 23, 2016
MONTPELLIER, FRANCE — French biotech firm Sensorion announced promising new preclinical results obtained with its investigational drug SENS-401, which is currently under development to treat acute sensorineural hearing loss. The results were presented at the Annual Meeting of the Society for Neuroscience (SfN) in San Diego, California, last week. Sensorion’s investigational drug, SENS-401 (R-azasetron besylate), aims to protect and preserve inner ear tissue,